## 6.7 Continued Access to Study Intervention after the End of

## the Study
Following the 6-month treatment period, long-term anticoagulation for secondary VTE prophylax
‐
is should be considered for patients with active cancer. The decision to continue anticoagulation
will depend on the type and stage of cancer, overall prognosis, periodic reevaluations of the risk
of recurrent VTE and bleeding, comorbidities, costs, and patients’ preferences.